KR820000367B1 - Process for preparing benzoic acid derivatives - Google Patents

Process for preparing benzoic acid derivatives Download PDF

Info

Publication number
KR820000367B1
KR820000367B1 KR7701677A KR770001677A KR820000367B1 KR 820000367 B1 KR820000367 B1 KR 820000367B1 KR 7701677 A KR7701677 A KR 7701677A KR 770001677 A KR770001677 A KR 770001677A KR 820000367 B1 KR820000367 B1 KR 820000367B1
Authority
KR
South Korea
Prior art keywords
benzoic acid
alkyl
ethyl
melting point
degreec
Prior art date
Application number
KR7701677A
Other languages
Korean (ko)
Inventor
히쩰 폴커
보이어 루디
카이젠 칼
파프 베르너
Original Assignee
헨리히 베커
훽스트 아크티엔 게젤샤프트
한스디테르 스템머
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헨리히 베커, 훽스트 아크티엔 게젤샤프트, 한스디테르 스템머 filed Critical 헨리히 베커
Priority to KR7701677A priority Critical patent/KR820000367B1/en
Application granted granted Critical
Publication of KR820000367B1 publication Critical patent/KR820000367B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms

Abstract

Benzoates[I; T = H, Cl, Br; W = carboxy; X = III (R1 = C2-8 alkyl, aralkyl, phenyl, C5-8 cycloalkyl; R2 =H, Cl, Br), IV(R3 = C5-8 alkyl, aralkyl, phenyl, C5-8 cycloalkyl); Y = C1-3 hydrocarbon; Z = H, halogen, alkyl, alkoxy, alkenyloxy useful as flood suger concentration lowering agent, were prepd. by reaction of II and XCOOH followed by removing formyl group. Thus, 2-butoxynicotinic acid was treated with ClCO2Me and 4-H2NCH2CH2C6H4CO2Et.HCl to give I[X = III(R1 = H; R2 = Bu); Y = Me; T,Z = H; W = CO2H, which was hydrolyzed to II(R2 = Et).

Description

벤조산 유도체류의 제조방법Method for producing benzoic acid derivatives

본 발명은 다음 일반식(Ⅰ)의 벤조산에 관한 것이다.The present invention relates to benzoic acid of the following general formula (I).

Figure kpo00001
Figure kpo00001

상기식에서In the above formula

T'는 수소 또는 할로겐, 바람직하기로는 염소 또는 브롬이고,T 'is hydrogen or halogen, preferably chlorine or bromine,

W'는 카복실그룹, 이들의 에스테르 또는 염이고,W 'is a carboxyl group, ester or salt thereof,

X'는X 'is

Figure kpo00002
Figure kpo00002

(상기 식에서(In the above formula

R1은 탄소수 2내지 8의 알킬알킬, 알킬 또는 할로겐에 의해서 치환될 수 있는 아르알킬, 페닐 또는 탄소수 5내지 8의 사이클로 알킬이고; R2는 수소 또는 할로겐, 바람직하기로는 염소 또는 브롬이며; R3는 탄소수 5내지 8의 알킬, 알킬 또는 할로겐에 의해서 치환될 수 있는 치환될 수 있는 아르알킬, 페닐 또는 탄소수 5내지 8인 사이클로 알킬이다)R 1 is aralkyl, phenyl or cycloalkyl of 5 to 8 carbon atoms which may be substituted by alkylalkyl, alkyl or halogen of 2 to 8 carbon atoms; R 2 is hydrogen or halogen, preferably chlorine or bromine; R 3 is optionally substituted alkyl, alkyl or substituted aralkyl, phenyl or cycloalkyl having 5 to 8 carbon atoms, which may be substituted by

Y'는 단일화학결합 또는 탄소수 1내지 3의 탄화수소 연쇄이며;Y 'is a single chemical bond or a hydrocarbon chain of 1 to 3 carbon atoms;

Z'는 수소, 할로겐, 알킬, 알콕시, 알콕시, 알콕시 또는 알케닐옥시이다.Z 'is hydrogen, halogen, alkyl, alkoxy, alkoxy, alkoxy or alkenyloxy.

상기 정의에서 알콕시, 알켄옥시, 알콕시 알콕시와 알킬아미노에서의 알킬잔기, 또는 알케닐과 알킬은 탄소수가 많지 않은 직쇄 또는 측쇄 탄화수소기이다.Alkoxy, alkeneoxy, alkoxy Alkoxy in the above definition, alkyl residues in alkoxy and alkylamino, or alkenyl and alkyl are straight-chain or branched hydrocarbon groups with low carbon number.

탄소수가 최고 6까지의 알킬, 알콕시, 알콕시, 알콕시 또는 알켄옥시그룹인 화합물들이 가장 바람직하다.Most preferred are compounds having up to 6 carbon atoms of alkyl, alkoxy, alkoxy, alkoxy or alkeneoxy groups.

상기 정의에 따른 할로겐중에서 무엇보다도 염소와 브롬이 가장 바람직하며, 상응하는 요드화합물은 추천할 만 한 것이 못된다. Y'는 2개의 탄소를 갖는 탄화수소 브릿지가가 바람직하며 이 부분은 알킬그룹에 의해서 치환될 수 있다.Of the halogens according to the above definition, chlorine and bromine are most preferred, and the corresponding iodine compounds are not recommended. Y 'is preferably a hydrocarbon bridge having two carbons, and this portion may be substituted by an alkyl group.

-CH2-CH2또는 -CH(CH3)-CH2그룹이 특별히 추천 할 만한 것이다. 탄소수 3이상의 다른 선상 또는 측쇄 탄화수소 브릿지는 바람직하지 못하다.The -CH 2 -CH 2 or -CH (CH 3 ) -CH 2 group is particularly recommended. Other linear or branched hydrocarbon bridges having 3 or more carbon atoms are undesirable.

본 발명에 따른 화합물의 제조방법은 다음과 같다.The preparation method of the compound according to the present invention is as follows.

다음 일반식(Ⅱ)의 아미노화합물 또는 이들의 포밀 화합물을 일반식 X'COOH의 반응성유도체와 반응시키고 임의로 포밀기를 분리시키고 얻어진 화합물을 이들의 유리산 또는 에스테르 또는 염으로 임의전환시킨다.The amino compound of formula (II) or a formyl compound thereof is then reacted with a reactive derivative of formula X'COOH, optionally separating the formyl group, and the resulting compound is optionally converted to their free acid or ester or salt.

Figure kpo00003
Figure kpo00003

상기의 출발물질인 아미노화합물은 기지이고 유사한 화합물을 제조하는 기지공정에 따라 어렵지 않게 제조될 수 있다.The starting compound, the amino compound, is known and can be prepared without difficulty according to a known process for producing a similar compound.

이들 아미노 화합물을 염기 존재하에서 X'COOH의 반응유도체, 예를 들면 할라이드류, 안하이드라이드류혼합된 안하이드라이드류, 아자이드류 또는 에스테르류와 반응시키는 것이 바람직하다.It is preferable to react these amino compounds with reaction derivatives of X'COOH, such as halides, anhydrides mixed anhydrides, azides or esters in the presence of a base.

본 발명화합물은 혈당-저하효과가 있으며, 화합물 자체를 그대로 또는 이들의 염 또는 에스테르류로 하여 토끼에게 10내지 400mg/kg 바람직하기로는 100mg/kg을 투여하여 하게도른-젠센의 방법, 또는 자동분석법에 의해 장기간 동안 혈당농도를 측정하면 본 혈당저하효과를 증명할 수 있다.The compound of the present invention has a blood sugar-lowering effect, and the compound is itself or as a salt or ester thereof, and the rabbit is administered to Hedor-Zensen by administering 10 to 400 mg / kg, preferably 100 mg / kg, or an automatic assay. By measuring the blood glucose level for a long time can prove the hypoglycemic effect.

본 발명의 화합물은 당뇨병 치료를 위해 혈당저하작용을 갖는 경구투여용 생성물 제조에 사용되고 자연그대로 사용할 수 있거나 또는 이들의 염형태 또는 에스테르류의 형태로 투여하거나 또는 염을 형성하기 위한 물질 예를 들면 알카리화제 즉 알카리금속 또는 알카리토류금속 수산화물, 탄산염류 또는 중탄산염류의 존재하에 투여하기도 한다. 적합한 의약생성물은 정제형태로 본 발명의 화합물에 부가하여 활석, 전분, 유당, 트라가칸트 또는 마그네슘 스테아레이트 같은 통상의 담체 또는 보조제를 포함한다. 활성성분으로서 본 발명화합물을 포함하는 약제, 예를 들어 정제 또는 부가제첨가(또는 부가제 없는) 산제는 적합한 용량 투여형태를 취한다. 단위당 투여량은 0.1내지 2g, 바람직하기로는 0.5내지 1g이다.The compounds of the present invention can be used in the preparation of oral administration products having hypoglycemic effects for the treatment of diabetes mellitus or can be used as such or administered in the form of their salts or esters or for forming salts such as alkalizing agents. That is, it may be administered in the presence of alkali metal or alkaline earth metal hydroxides, carbonates or bicarbonates. Suitable medicinal products include conventional carriers or auxiliaries such as talc, starch, lactose, tragacanth or magnesium stearate in addition to the compounds of the present invention in tablet form. Pharmaceuticals, such as tablets or additives (or no additives), comprising the compounds of the present invention as active ingredients, take suitable dosage forms. The dosage per unit is 0.1 to 2 g, preferably 0.5 to 1 g.

이러한 범위이상 또는 이하의 용량을 투여할 수 있으며 바람직하다면 투여하기 전에 분배 또는 복합할 수 있다.Doses above or below this range may be administered and, if desired, may be dispensed or combined prior to administration.

본 발명의 벤조산 유도체는 당뇨병치료를 위하여 자연그대로 사용하거나 또는 다른 당노병치료제 즉, 혈당저하 작용을 갖는 설포닐우레아류, 뿐만 아니라 다른 화학구조를 갖는 비구아니드류, 특히 페닐에틸-비구아니드 또는 디메틸 비구아니드와 혼합하여 사용할 수 있다.The benzoic acid derivatives of the present invention can be used as is for the treatment of diabetes mellitus or other anti-diabetic agents such as sulfonylureas having hypoglycemic action, as well as biguanides having other chemical structures, especially phenylethyl-biguanide or It can be used in combination with dimethyl biguanide.

다음 실시예는 본 발명 화합물의 합성을 위한 다양한 공정을 보여주며 본 발명을 제한하는 것이 아니다.The following examples illustrate various processes for the synthesis of the compounds of the invention and do not limit the invention.

[실시예 1]Example 1

4-(2-<부톡시-니코틴아미도>-에틸)-벤조산4- (2-butoxy-nicotinamido-ethyl) -benzoic acid

2-부톡시-니코틴산(아세트산 에틸에스테르로부터, 융점 54내지 56℃) 6.5g을 테트라하이드로푸란 150ml에 용해시킨다. 트리에틸아민 14.5ml을 첨가후 욕을 0℃로 냉각하고 클로로포름산 메틸에스테르 3.2ml를 적가한다. 진탕을 0℃에서 1시간 동안 계속한 후 4-(2-아미노에틸)-벤조산 에틸에스테르-하이드로 클로라이드 7.6g을 첨가하여 진탕을 0℃에서 1시간 동안 계속하고 계속하여 상온에서 4시간 동안 진탕시킨다. 욕을 증발시키고 잔류물을 아세트산 에틸 에스테르와 혼합한다. 물, 탄산수소나트륨용액, 묽은 염산과 물로 세척한 후 이 아세트산 에틸에스테르 용액을 건조시키고 감압하에서-증발시킨다. 얻어진 4-(2-<2-부톡시-니코틴아미도>-메틸)-벤조산 에틸 에스테르를 2N 수산화나트륨 용액 25m와 에탄올 50ml 중에서 3시간 동안 환류시킨다. 용매를 증류제거한 후, 생성물을 묽은 아세트산으로 산성화시키고 흡인여과한 다음 아세트산 에스테르로부터 재결정시킨다. 수득된 4-(2-<2-부톡시-니코틴아미도>-에틸)-벤조산은 융점이 147내지 149℃이다.6.5 g of 2-butoxy- nicotinic acid (from acetic acid ethyl ester, melting | fusing point 54-56 degreeC) are melt | dissolved in 150 ml of tetrahydrofuran. After adding 14.5 ml of triethylamine, the bath was cooled to 0 ° C. and 3.2 ml of chloroformic acid methyl ester was added dropwise. The shaking was continued at 0 ° C. for 1 hour, followed by addition of 7.6 g of 4- (2-aminoethyl) -benzoic acid ethyl ester-hydrochloride, and the shaking was continued at 0 ° C. for 1 hour, followed by shaking at room temperature for 4 hours. . The bath is evaporated and the residue is mixed with acetic acid ethyl ester. After washing with water, sodium hydrogencarbonate solution, dilute hydrochloric acid and water, the acetic acid ethyl ester solution is dried and evaporated under reduced pressure. The obtained 4- (2- <2-butoxy-nicotinamido> -methyl) -benzoic acid ethyl ester was refluxed in 25 m of 2N sodium hydroxide solution and 50 ml of ethanol for 3 hours. After distilling off the solvent, the product is acidified with dilute acetic acid, filtered off with suction and recrystallized from acetic acid ester. Obtained 4- (2- <2-butoxy- nicotinamido> -ethyl) -benzoic acid has melting | fusing point of 147-149 degreeC.

유사한 방법으로 다음과 같은 것이 얻어진다. 2-사이클로헥실옥시-니코틴산(에탄올로부터 재결정 융점 57내지 58℃)으로부터 4-(2-<2-사이클로헥실옥시-니코틴아미도>-에틸)-벤조산 융점 212내지 213℃ (메탄올/디옥산으로부터 재결정),In a similar manner the following is obtained. 2- (2- <2-cyclohexyloxy-nicotinamido> -ethyl) -benzoic acid melting point 212-213 degreeC from 2-cyclohexyloxy- nicotinic acid (recrystallization melting point 57-58 degreeC from ethanol) (methanol / di Recrystallized from oxane),

2-부톡시-5-클로로-니코틴산(아세틴산(에틸에스테르로부터 재결정 융점 99내지 101℃)으로부터 4-(2-<2-부톡시-5-클로로-니코틴아미도>-에틸)-벤조산 융점 164내지 166℃ (메탄올/아세틴산 에틸에스테르로부터 재결정),2- (2- <2-butoxy-5-chloro- nicotinamido> -ethyl) -benzoic acid from 2-butoxy-5-chloro- nicotinic acid (acetic acid (recrystallization melting point 99-101 degreeC from ethyl ester) Melting point 164-166 캜 (recrystallized from methanol / acetinic acid ethyl ester),

2-페녹시-니코틴산(아세틴산 에틸 에스테르로부터 재결정 융점 181내지 182℃)으로부터 4-(2-<2-페녹시-니코틴아미도>-에틸)-벤조산 융점 162내지 163℃ (메탄올로부터 재결정),4- (2- <2-phenoxy-nicotinamido> -ethyl) -benzoic acid melting point 162-163 degreeC (recrystallization from methanol from 2-phenoxy- nicotinic acid (recrystallization melting | fusing point 181 to 182 degreeC from ethyl acetate ethyl ester)) ),

2-에톡시-니코틴산(에탄올로부터 재결정 융점 89내지 91℃)으로부터, 4-(2-<2-에톡시-니코틴아미도>-에틸)-벤조산 융점 138내지 140℃ (에탄올로부터 재결정),From 2-ethoxy-nicotinic acid (recrystallization melting point 89-91 degreeC from ethanol), 4- (2- <2-ethoxy- nicotinamido> -ethyl) -benzoic acid melting point 138-140 degreeC (recrystallization from ethanol),

2-에톡시-5-클로로-니코틴산(에탄올로부터 재결정 융점 115내지 117℃)으로부터 4-(2-<2-에톡시-5-클로로-니코틴아미도>-에틸)-벤조산 융점 150내지 151℃ (메탄올로부터 재결정),4- (2- <2-ethoxy-5-chloro-nicotinamido> -ethyl) -benzoic acid melting point 150-151 degreeC from 2-ethoxy-5- chloro- nicotinic acid (recrystallization melting point 115-117 degreeC from ethanol) (Recrystallized from methanol),

2-프로폭시-니코틴산(에탄올로부터 재결정 융점 48내지 50℃)으로부터 4-(2-<2-프로폭시-니코틴아미도>-에틸)-벤조산 융점 157내지 158℃ (메탄올로부터 재결정),4- (2- <2-propoxy-nicotinamido> -ethyl) -benzoic acid melting point 157-158 degreeC (recrystallization from methanol) from 2-propoxy- nicotinic acid (recrystallization melting point 48-50 degreeC from ethanol),

2-클로로-2-프로폭시-니코틴산(에탄올로부터 재결정 융점 102내지 103℃)으로부터 4-(2-<5-클로로-2-프로폭시-니코틴아미도>-에틸)-벤조산 융점 173내지 174℃ (아세틴산 에틸에스테르로부터 재결정),2- (2- <5-chloro-2-propoxy-nicotinamido> -ethyl) from 2-chloro-2-propoxy-nicotinic acid (recrystallization melting point 102-103 degreeC from ethanol)-benzoic acid melting point 173-174 degreeC (Recrystallized from acetic acid ethyl ester),

2-펜틸옥시-니코틴산(융점 37내지 39℃)으로부터 4-(2-<2-펜틸옥시-니코틴아미도>-에틸)-벤조산 융점 154내지 156℃ (에탄올로부터 재결정),4- (2- <2-pentyloxy-nicotinamido> -ethyl) -benzoic acid melting point 154-156 degreeC (recrystallized from ethanol) from 2-pentyloxy- nicotinic acid (melting point 37-39 degreeC),

5-클로로-2-펜틸옥시니코틴산(에탄올/H2O로부터 재결정 융점 98내지 100℃)으로부터 4-(2-<5-클로로-2-펜틸옥시-니코틴아미도>-에틸)-벤조산 융점 125내지 127℃ (에탄올로부터 재결정),5-chloro-2-pentyloxy acid from (ethanol / H 2 O-melting recrystallization from 98 to 100 ℃) 4- (2- <5- chloro-2-pentyloxy-nicotinamide FIG amino> ethyl) -benzoic acid Melting point 125 To 127 ° C. (recrystallized from ethanol),

2-옥틸옥시-니코틴산(융점 53내지 54℃)으로부터 4-(2-<2-옥틸옥시-니코틴아미도>-에틸)-벤조산 융점 104내지 106℃ (에탄올로부터 재결정),4- (2- <2-octyloxy-nicotinamido> -ethyl) -benzoic acid melting point 104-106 degreeC (recrystallized from ethanol) from 2-octyloxy- nicotinic acid (melting point 53-54 degreeC),

5-클로로-2-옥틸옥시ㅡ니코틴산(에탄올로부터 재결정 융점 98내지 100℃)으로부터 4-(2-<5-클로로-2-옥틸옥시-니코틴아미도>-에틸)-벤조산 융점 115내지 117℃ (에탄올로부터 재결정),From 5-chloro-2-octyloxy nicotinic acid (recrystallization melting point 98-100 degreeC from ethanol) 4- (2- <5-chloro-2-octyloxy-nicotinamido> -ethyl) -benzoic acid melting point 115-117 degreeC (Recrystallized from ethanol),

5-클로로-2-사이클로헥실옥시ㅡ니코틴산(아세틴산 에틸에스테르로부터 재결정 융점 65내지 67℃)으로부터 4-(2-<5-클로로-2-사이클로헥실옥시-니코틴아미도>-에틸)-벤조산 융점 165내지 167℃ (에탄올로부터 재결정),5- (2- <5-chloro-2-cyclohexyloxy-nicotinamido> -ethyl) from 5-chloro-2-cyclohexyloxy nicotinic acid (recrystallization melting point 65-67 degreeC from acetinic acid ethyl ester) -Benzoic acid melting point 165-167 캜 (recrystallized from ethanol),

2-벤질옥시-니코틴산(에탈올로부터 재결정 융점 57내지 58℃)으로부터 4-(2-<2-벤질옥시-니코틴아미도>-에틸)-벤조산 융점 184내지 185℃ (메탄올로부터 재결정),4- (2- <2-benzyloxy-nicotinamido> -ethyl) -benzoic acid melting point 184-185 degreeC (recrystallization from methanol) from 2-benzyloxy- nicotinic acid (recrystallization melting point 57-58 degreeC from ethanol),

[실시예 2]Example 2

4-(2-<1-벤질-1,2-디하이드로-2-옥소-니코틴아미도>-에틸)-벤조산4- (2- (1-benzyl-1-, 2-dihydro-2-oxo-nicotinamido> -ethyl) -benzoic acid

아세톤 20ml을 상응하는 량(1물)의 아세테이트 나트륨을 포함하는 약 1몰의 3-(2-아미노에틸)-벤조산 용액 16ml에 첨가하고 여기에 1-벤질-1,2-디하이드로-2-옥소-니코틴산 클로라이드(1-벤질-1,2-디하이드로-2-옥소-니코틴산과 티오닐 클로라이드로부터 제조된) 3.7g을 진탕 냉각하면서 첨가한다. 진탕을 상온에서 1시간 동안 게속하고 아세톤을 감압하에서 제거한 후 묽은 염산을 잔류물에 첨가한다. 침전된 생성물을 흡인여과하고 묽은 암모니아수로부터 재침전시키고 묽은 메탄올로 재결정화시키면 융점 150내지 152℃와 171내지 173℃인 4-(2-<1-벤질디하이드로-1,2-2-옥소-니코틴아미도>-에틸)-벤조산이 얻어진다. 유사한 방법으로 다음과 같은 것이 얻어진다:20 ml of acetone are added to 16 ml of a solution of about 1 mole of a 3- (2-aminoethyl) -benzoic acid containing a corresponding amount of sodium acetate, and to which 1-benzyl-1,2-dihydro-2--2- 3.7 g of oxo-nicotinic acid chloride (prepared from 1-benzyl-1,2-dihydro-2-oxo-nicotinic acid and thionyl chloride) are added with shaking cooling. The shaking is continued at room temperature for 1 hour, the acetone is removed under reduced pressure, and diluted hydrochloric acid is added to the residue. The precipitated product was suction filtered, reprecipitated from dilute ammonia water and recrystallized from dilute methanol to give 4- (2- <1-benzyldihydro-1,2--2-oxo-) having a melting point of 150 to 152 ° C and 171 to 173 ° C. Nicotinamido-> ethyl) -benzoic acid is obtained. In a similar way the following is obtained:

1-사이클로헥실-1,2-디하이드로-2-옥소-니코틴산 클로라이드로부터 4-(2-<1-사이클로헥실-1,2-디하이드로-2-옥소-니코틴아미도>-에틸)-벤조산 융점 176℃ (에탄올로부터 재결정),4- (2- (1-cyclohexyl-1,2-dihydro-2-oxo-nicotinamido> -ethyl) -benzoic acid from 1-cyclohexyl 1-2, 2-dihydro-2- oxo- nicotinic acid chloride Melting point 176 ° C. (recrystallized from ethanol),

1-(4-메틸사이클로헥실)-1,2-디하이드로-2-옥소-니코틴산 클로라이드로부터 4-(2-<1-(4-메틸사이클로헥실)-1,2-디하이드로-2-옥소-니코틴아미도>-에틸)벤조산 융점 202℃ (에탄올로부터 재결정),4- (2- <1- (4-methylcyclohexyl) -1,2-dihydro-2-oxo from 1- (4-methylcyclohexyl) -1,2-dihydro-2-oxo-nicotinic acid chloride -Nicotinamido-> ethyl) benzoic acid melting | fusing point 202 degreeC (recrystallized from ethanol),

[실시예 3]Example 3

4-(2-<2-에톡시-니코틴아미도>-에틸)-벤조산4- (2- (2-ethoxy-nicotinamido> -ethyl) -benzoic acid

융점 205내지 206℃ (아세틴 에스테르로부터)인-4-(2-클로로-니코틴아미도>-에틸)-벤조산(연속 검화법에 의해 2-클로로-니코틴산과 4-(2-아미노에틸)-벤조산 에틸 에스테르-하이드로클로라이드의 혼합 무수물로부터 제조된) 1.52g을 소디움 0.23g을 함유한 에탄올용액 50ml에 용해시킨다. 욕을 2시간 환류시키며 감압하에서 농축, 물에 용해하고 묽은 아세트산으로 산성화시킨다. 생성물을 클로로포름에 용해하여 추출(2번)하고 클로로포름층을 황산 나트륨상에서 건조 농축시킨다. 고체잔류물을 에탄올로 재결정화시켜 얻어진 4-(2-<2-에톡시-니코틴아미도>-에틸)-벤조산은 융점 138내지 140℃이다. 실시예 1에 따라 얻어진 산과 함께 혼합된 융점은 저하없음.Melting point 205-206 degreeC (from acetin ester) 4- (2-chloro- nicotinamido> -ethyl) -benzoic acid (2-chloro- nicotinic acid and 4- (2-aminoethyl)-by a continuous saponification method 1.52 g) (prepared from a mixed anhydride of benzoic acid ethyl ester-hydrochloride) is dissolved in 50 ml of an ethanol solution containing 0.23 g of sodium. The bath is refluxed for 2 hours, concentrated under reduced pressure, dissolved in water and acidified with diluted acetic acid. The product is dissolved in chloroform and extracted (twice) and the chloroform layer is concentrated to dryness over sodium sulfate. 4- (2- <2-ethoxy-nicotinamido> -ethyl) -benzoic acid obtained by recrystallizing the solid residue with ethanol has a melting point of 138 to 140 캜. The melting point mixed with the acid obtained according to Example 1 did not decrease.

[실시예 4]Example 4

4-(2-<2-에톡시-5-클로로-니코틴아미도>-에틸)-벤조산4- (2- (2-ethoxy-5-chloro-nicotinamido> -ethyl) -benzoic acid

4-(2-<2-에톡시-니코틴아미도>-에틸)-벤조산 3.14g을 물 200ml에 현탁시키고 60내지 70℃ 온도를 갖는 오일욕에서 3시간 가열한다. 진탕하면서 기체상의 염소를 현탁액에 도입한다. 반응이 완결된 후 (박층 크로마토 그라피에 의해서)욕을 냉각하고 침전물을 흡인여과하여 메탄올로 재결정화시킨다. 얻어진 4-(2-<2-에톡시-5-클로로-니코틴아미도>-에틸)-벤조산은 융점이 150내지 151℃이고 실시예 1에 따라 얻어진 물질과 함께 혼합된 융점에서 저하없음을 보여준다.3.14 g of 4- (2- <2-ethoxy-nicotinamido> -ethyl) -benzoic acid are suspended in 200 ml of water and heated for 3 hours in an oil bath having a temperature of 60 to 70 캜. Gaseous chlorine is introduced into the suspension with shaking. After completion of the reaction (by thin layer chromatography), the bath is cooled and the precipitate is suction filtered to recrystallize from methanol. Obtained 4- (2- <2-ethoxy-5-chloro-nicotinamido> -ethyl) -benzoic acid has a melting point of 150 to 151 캜 and shows no degradation at the melting point mixed with the material obtained according to Example 1 .

Claims (1)

일반식(Ⅱ)의 아미노 화합물 또는 이의 포밀 화합물을 일반식 X'COOH의 반응유도체와 반응시킨 후, 생성물중의 포밀기는 제거시킴을 특징으로하여 일반식(Ⅰ)의 벤조산 유도체를 제조하는 방법A method for preparing the benzoic acid derivative of formula (I), wherein the amino compound of formula (II) or a formyl compound thereof is reacted with a reaction derivative of formula X'COOH, and then the formyl group in the product is removed.
Figure kpo00004
Figure kpo00004
상기 식에서 T'는 수소 또는 할로겐, 특히 염소 또는 브롬이며, W'는 카복실그룹, 이들의 에스테르 또는 염이며,Wherein T 'is hydrogen or halogen, in particular chlorine or bromine, W' is a carboxyl group, ester or salt thereof,
Figure kpo00005
Figure kpo00005
[상기식에서, R1은 탄소수 2내지 8의 알킬, 알킬 또는 할로겐에 의해 치환될 수도 있는 아르알킬, 페닐 또는 탄소수 5내지 8의 사이클로알킬이고, R2는 수소 또는 할로겐, 특히 염소 또는 브롬이며, R3는 탄소수 5내지 8의 알킬, 알킬 또는 할로겐에 의해 치환될 수도 있는 아르알킬, 페닐 또는 탄소수 5내지 8의 사이클로 알킬이다][Wherein R 1 is aralkyl, phenyl or cycloalkyl of 5 to 8 carbon atoms, which may be substituted by alkyl, alkyl or halogen of 2 to 8 carbon atoms, R 2 is hydrogen or halogen, in particular chlorine or bromine, R 3 is aralkyl, phenyl or cycloalkyl of 5 to 8 carbon atoms, which may be substituted by alkyl, alkyl or halogen of 5 to 8 carbon atoms; Y'는 탄소수 1내지 3의 탄화수소 연쇄 또는 단일화학결합이며, Z는 수소, 할로겐, 알킬, 알콕시알콕시 알콕시 또는 알케닐옥시이다.Y 'is a hydrocarbon chain or a single chemical bond having 1 to 3 carbon atoms, and Z is hydrogen, halogen, alkyl, alkoxyalkoxy alkoxy or alkenyloxy.
KR7701677A 1977-09-24 1977-09-24 Process for preparing benzoic acid derivatives KR820000367B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7701677A KR820000367B1 (en) 1977-09-24 1977-09-24 Process for preparing benzoic acid derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7701677A KR820000367B1 (en) 1977-09-24 1977-09-24 Process for preparing benzoic acid derivatives

Publications (1)

Publication Number Publication Date
KR820000367B1 true KR820000367B1 (en) 1982-03-25

Family

ID=19204623

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7701677A KR820000367B1 (en) 1977-09-24 1977-09-24 Process for preparing benzoic acid derivatives

Country Status (1)

Country Link
KR (1) KR820000367B1 (en)

Similar Documents

Publication Publication Date Title
US4181658A (en) Certain nicotinamido-n-benzoic acid derivatives
EP0288973B1 (en) Benzothiazolinone derivatives, their production and pharmaceutical composition
KR20020008221A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated recep tor(PPAR)α
DE2500157A1 (en) BENZOIC ACIDS AND DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
US6096770A (en) Anthranilic acid analogs
JPH08325263A (en) New 2-amino-3-phenylpropionic acid derivative
JPH035459A (en) Substituted (quinolin-2-ylmethoxy)phenylacyl- sulfonamides and -cyanamides
WO1997032863A1 (en) Thiazolidine-2,4-dione derivatives
US4542127A (en) Antidiabetic salicylic acid derivatives
JPS60142981A (en) 3-indolecarboxamide derivative
CS236668B2 (en) Manufacturing process of aralkylamides 2-substituted aminophenylalkancarboxyle and amino-3-pyridylalkancarboxyl acides
US4158063A (en) Acylamino(alkyl)benzene derivatives and process for preparing them
KR820000367B1 (en) Process for preparing benzoic acid derivatives
LT3798B (en) Method for the preparation of n,n&#39;-bis(alkoxyalkyl)-pyrimidine-2,4-dicarboxylic acids diamides and use thereof
JPH0660152B2 (en) Novel oxalic acid derivative and hypoglycemic agent containing the compound
AU734786B2 (en) Anthranilic acid analogs
JPH08325250A (en) New substituted phenol derivative
KR880001715B1 (en) Process for preparing 1-furyl-3,4-dihydro-isoquinolines
JPS59219268A (en) Uracil derivative
JP3190717B2 (en) New substituted itaconic acid derivatives
US4182775A (en) Benzoic acids and process for their preparation
JPH052675B2 (en)
JP2686861B2 (en) Novel benzylidene succinic acid derivative
EP0424901A1 (en) Dihydropyridine derivatives and pharmaceutical compositions
JPH0499770A (en) Rhodanine derivative